Six days ago, in our October 8, 2026 forensic investigation—The $40B Oncology Paradox: A Forensic Deep Dive into Revolution Medicines ($RVMD), the FDA Review, and the G12D Efficacy Chasm—we documented a critical structural crack in the precision oncology sector’s most crowded consensus trade.

While Wall Street priced Revolution Medicines (NASDAQ: RVMD) at a $40.3 billion to $41.6 billion market capitalization on the premise that its newly approved multi-RAS(ON) inhibitor Rasonque (daraxonrasib / RMC-6236) would serve as an unassailable universal monotherapy across pancreatic ductal adenocarcinoma (PDAC), the U.S. Food and Drug Administration’s unredacted CDER Multidiscipline Review of the Phase 3 RASolute 302 trial (N=228) revealed an acute bimodal split. Whereas daraxonrasib achieved a 50% confirmed objective response rate (cORR) in KRAS G12V (~31% of PDAC), efficacy in KRAS G12D—the dominant mutation driving ~40% to 43% of all pancreatic cancers—dropped to 24% cORR (23/95). We demonstrated that this 26-percentage-point chasm is governed by hard structural biophysics: the negatively charged Asp12 (-CH₂-COO⁻) carboxylate side chain introduces electrostatic repulsion and steric hindrance against the Cyclophilin A (CypA) immunophilin chaperone required by daraxonrasib’s tri-complex mechanism, while off-tumor wild-type RAS (KRAS/NRAS/HRAS) inhibition caps dosing at 300 mg QD due to mucosal ulceration, stomatitis, and rash.

On the morning of October 14, 2026, the competitive consequence of that exact G12D vulnerability materialized in an official SEC Form 8-K filing (Accession No. 0001104659-26-115687) and press release from Verastem Oncology (NASDAQ: VSTM).

Reporting its first multi-tumor U.S. clinical dataset from the Phase 1/2 TARGET-D 101 trial (NCT07020221) for VS-7375 (GFH375)—an oral, non-chaperone, direct KRAS G12D dual ON/OFF inhibitor licensed from Shanghai-based GenFleet Therapeutics—Verastem placed a prominent dark-blue callout box directly onto Slide 12 of its SEC-furnished investor presentation: “Daraxonrasib KRAS G12D: 24% cORR (23/95)”, contrasting RVMD’s subgroup performance against VS-7375’s 50% cORR (4/8) in 2L PDAC and 41% cORR (9/22) in 2L+ PDAC (including two complete responses [CRs]) at 900 mg once daily (QD):

Verastem Oncology SEC Form 8-K Exhibit 99.3 Slide 12: Cross-Trial Comparison in KRAS G12D Pancreatic Cancer

Simultaneously, Verastem executed a classic triple-catalyst corporate maneuver before the opening bell:

  1. Clinical Data & Phase 3 Alignment: Disclosed multi-tumor efficacy across PDAC, NSCLC, and CRC alongside FDA protocol alignment on a three-arm Phase 3 first-line mPDAC trial (TARGET-D 301, N=354) featuring a chemotherapy-free arm (VS-7375 900 mg QD + anti-EGFR mAb).
  2. Massive Balance Sheet Dilution: Priced an underwritten public offering of 30,937,500 common shares at $8.00 per share plus 312,503 pre-funded warrants at $7.9999 (led by Jefferies, Guggenheim Securities, Cantor Fitzgerald, and B. Riley) to raise $250 million in gross proceeds—a +7.4% premium to its October 13 closing price of $7.45 (which had tumbled -9.70% during the prior session as wall-crossed institutions positioned for the bookbuild).
  3. C-Suite Succession: Announced that longtime President and CEO Daniel W. Paterson will retire effective January 1, 2027, handing leadership to Board member and former AVEO Pharmaceuticals CEO Michael P. Bailey.

Across biotechnology desks, the data drop immediately ignited a three-way valuation and scientific debate linking Verastem ($VSTM, ~$675M pre-deal / ~$925M post-deal market cap), Erasca ($ERAS, ~$5.4B–$5.6B market cap at $14.78), and Revolution Medicines ($RVMD, ~$40.5B market cap at ~$188):

“$VSTM data today. New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers. Own shares. $RVMD $ERAS”
— Michel Doepke (@doepke_michel), Biotech Investor, October 14, 2026

“So VSTM is the new RVMD ?”
— Hazem Samara (@hazemsamara), Market Commentator, October 14, 2026

“Why didn’t $VSTM submit an abstract for ESMO to present its G12D data?”
— Adam Feuerstein (@adamfeuerstein), Senior Biotech Journalist, October 14, 2026

“$VSTM - CRC data intriguing but too low N to excite. Clearly have a drug in PDAC & NSCLC, but will take time & execution. 2% discontinuation = tolerability edge (which mgmt contends allowed them to dose higher and achieve better saturation, ultimately better efficacy… TBD)”
— Jonathan Faison (@jfais20), Biotech Analyst, October 14, 2026

Rather than accepting corporate slide decks at face value or collapsing into binary cheerleading, this investigation applies our 8-phase “Panning for Gold” critical thinking framework across the entire RAS oncology triad ($VSTM, $ERAS, $RVMD). We dissect why VS-7375’s direct salt-bridge chemistry corroborates our October 8 biophysical critique of $RVMD, expose the buried U.S. 600 mg denominators (4/27 = 14.8% cORR in PDAC; 3/24 = 12.5% cORR in CRC) that Verastem omitted as percentages in its press release text, answer Adam Feuerstein’s ESMO 2026 question using clinical cutoff math, interrogate why Erasca ($ERAS) trades at an 8x valuation multiple over $VSTM despite a tiny N=7 PDAC denominator and an active U.S. Patent No. 12,409,225 / trade secret dispute with $RVMD, and synthesize decision-grade If-Clauses into an explicit institutional verdict.

┌────────────────────────────────────────────────────────────────────────────────────────────────────────────┐
│           THE 2026 RAS ONCOLOGY TRIAD: FORENSIC VALUATION, MECHANISM & CLINICAL SCORECARD                  │
├──────────────────────────┬──────────────────────────┬──────────────────────────┬───────────────────────────┤
│ DIMENSION / METRIC       │ VERASTEM ($VSTM)         │ ERASCA ($ERAS)           │ REVOLUTION MED ($RVMD)    │
├──────────────────────────┼──────────────────────────┼──────────────────────────┼───────────────────────────┤
│ Lead KRAS G12D Asset     │ VS-7375 (GFH375)         │ ERAS-0015 (+ ERAS-4001)  │ Daraxonrasib (+ Zoldon.)  │
│ Molecular Mechanism      │ Direct G12D ON/OFF Small │ Pan-RAS CypA Molecular   │ Pan-RAS(ON) CypA Glue     │
│                          │ Molecule (No CypA Glue)  │ Glue (eras-4001=panKRAS) │ (+ G12D Covalent Glue)    │
│ Origin / Licensor        │ GenFleet (Ex-China Rts)  │ Joyo Pharmatech (Global) │ In-House / Warp Drive Bio │
│ Share Price (Oct 13/14)  │ $7.45 Close / $8.00 Deal │ $14.78 (-4.40%)          │ ~$188.00                  │
│ Market Capitalization    │ ~$675M Pre / ~$925M Post │ ~$5.4B – $5.6B           │ ~$40.3B – $41.6B          │
│ Pro-Forma Cash Balance   │ ~$455M (Q3 $173M + $250M │ ~$950M+ (Q2 $384M +      │ ~$3.9B (Q2 2026 10-Q;     │
│                          │ Deal + $50M Oberland)    │ July $632.5M Offering)   │ $525M–$550M/Qtr Burn)     │
│ 2L+ PDAC G12D Efficacy   │ 900mg: 41% cORR (9/22;   │ 32mg: 57% uORR_8wk (4/7  │ Daraxonrasib: 24% cORR    │
│ (Confirmed vs Unconf.)   │ 2L: 50% [4/8], 2 CRs)    │ unconf. across G12X)     │ in G12D (23/95, Phase 3)  │
│ Hidden Dose / Subtype    │ 600mg US PDAC collapsed  │ Only N=7 at 32mg RDE;    │ G12V 50% vs G12D 24%;     │
│ Vulnerability            │ to 14.8% cORR (4/27)!    │ G12D vs G12V unsplit     │ Zoldonrasib cORR 15% (6/40│
│ Wild-Type RAS Toxicity   │ 0% Mucositis/Stomatitis; │ Claims 0% TRAE discont.  │ High Rash, Stomatitis,    │
│ & Discontinuation Rate   │ 4% Gr1-2 Rash; 2% Disc.  │ in Ph1 (small N, early)  │ Mucositis; Dose-Capped    │
│ Legal / Governance Risk  │ 34.5% Share Dilution on  │ RVMD Patent '225 & Trade │ $149.7M Insider Selling / │
│                          │ Oct 14 + CEO Retirement  │ Secret Threat + Lawsuits │ $0 Bought; 20/20 Buy Bias │
│ Institutional Stance     │ SPECULATIVE ACCUMULATE   │ UNDERWEIGHT / AVOID      │ TACTICAL SHORT / TRIM     │
│                          │ ON OFFERING CHURN ($8)   │ (Litigation + 8x VSTM EV)│ (G12D Monopoly Broken)    │
└──────────────────────────┴──────────────────────────┴──────────────────────────┴───────────────────────────┘

1. Phase 1: Issue Classification, Boundary Framing & Falsifiability Criteria

Following Chapter 2 of Browne & Keeley’s Asking the Right Questions, we separate our inquiry into explicit Descriptive (mechanistic/statistical) and Prescriptive (capital allocation/valuation) questions, anchored by strict falsifiability criteria.

Core Investigative Questions

  1. Descriptive (Biophysical & Clinical): Does Verastem’s VS-7375 overcome the Cyclophilin A steric/electrostatic potency ceiling that restricted Revolution Medicines’ daraxonrasib to a 24% cORR (23/95) in KRAS G12D PDAC—and why did VS-7375 require a 50% dose escalation from 600 mg QD (the Chinese RP2D) to 900 mg QD in U.S. patients to achieve a 41% confirmed ORR (9/22)?
  2. Descriptive (Regulatory & Statistical): What do the exact binomial confidence intervals, buried 600 mg cohort denominators (4/27 in PDAC, 3/24 in CRC), ESMO 2026 abstract timelines, and Phase 3 TARGET-D 301 crossover rules reveal about the statistical maturity and regulatory risk of VS-7375?
  3. Prescriptive (Relative Valuation Across $VSTM, $ERAS, $RVMD): In light of Verastem’s October 14 data and $250M financing at $8.00/share, how should institutional portfolios weight Verastem (~$925M post-deal market cap), Erasca (~$5.5B market cap), and Revolution Medicines (~$40.5B market cap)?

Explicit Falsifiability Criteria

What specific empirical evidence would prove our thesis wrong across each leg of the triad?

  • For Verastem ($VSTM Bullishness Falsified): If the Phase 2 registration-directed TARGET-D 201 trial (NCT07644559, N=80–120 in 2L KRAS G12D PDAC at 900 mg QD, readout Q2 2027) regresses from the Phase 1/2 41%–50% cORR down to ≤ 25% cORR by blinded independent central review (BICR), or if cumulative exposure beyond 6 months at 900 mg QD triggers late-onset hepatotoxicity or >15% treatment discontinuations.
  • For Revolution Medicines ($RVMD Skepticism Falsified): If the Phase 3 RASolute 309 doublet (daraxonrasib + zoldonrasib, NCT06915220) or frontline zoldonrasib + chemo (RASolute 305) demonstrates >55% confirmed ORR in G12D PDAC with <10% discontinuations and successfully blocks community oncologists from switching G12D patients to direct non-chaperone oral G12D inhibitors (VS-7375, Incyte’s INCB161734).
  • For Erasca ($ERAS Skepticism Falsified): If ERAS-0015 maintains a confirmed ORR ≥ 45% across ≥ 50 specifically KRAS G12D-mutated U.S. PDAC patients in AURORAS-1 (NCT06983743) and Erasca secures a declaratory judgment invalidating or proving non-infringement of Revolution Medicines’ U.S. Patent No. 12,409,225 and dismissing all trade secret claims.

2. Phase 2: Primary Source Excavation & Traceability Matrix

In accordance with our anti-echo chamber standard, every clinical denominator, pharmacokinetic curve, balance sheet figure, and legal claim in this report is traced directly to canonical primary SEC filings, ClinicalTrials.gov registries, and peer-reviewed literature:

                                   PRIMARY ARTIFACT TRACEABILITY MATRIX
    
     Entity / Domain  Canonical Primary Source             Accession / Identifier     Key Verified Fact
    ─────────────────────────────────────────────────────────────────────────────────────────────────────────
     Verastem ($VSTM) SEC Form 8-K & Exhibit 99.3 (60p)    0001104659-26-115687       900mg PDAC: 41% cORR (9/22),
     Clinical & Deal  Filed October 14, 2026               CIK 0001526119             2L 50% (4/8); 600mg: 4/27 cPR;
                                                                                      Q3 Cash: $172.8M; Q3 Rev: ~$24M
    ─────────────────────────────────────────────────────────────────────────────────────────────────────────
     Verastem ($VSTM) SEC Form 10-Q (Q2 2026) & Offering   0001104659-26-092007       90.5M basic shs (+9.7M PFWs);
     Capital Struct.  Press Release (Oct 14, 2026)         CIK 0001526119             +30.94M shs @ $8.00 + 312.5k PFW
    ─────────────────────────────────────────────────────────────────────────────────────────────────────────
     Verastem ($VSTM) ClinicalTrials.gov Registries        NCT07020221 (TARGET-D 101) Ph1/2 Multi-Tumor (n>200 enrolled)
     Trial Protocols  TARGET-D 101 / 201 / 202 / 203       NCT07644559 / 782 / 795    Ph2 Reg-Directed PDAC, NSCLC, CRC
    ─────────────────────────────────────────────────────────────────────────────────────────────────────────
     Erasca ($ERAS)   SEC Form 10-Q (Q2 2026) & Form 8-K   0001193125-26-344611       312.6M shs (pre-July $632.5M deal);
     Financial & IP   Patent/Trade Secret Disclosure       CIK 0001761918             $150M Joyo IPR&D; RVMD Pat. '225
    ─────────────────────────────────────────────────────────────────────────────────────────────────────────
     Erasca ($ERAS)   ClinicalTrials.gov & AURORAS-1       NCT06983743 (AURORAS-1)    32mg QD: 57% uORR_8wk (4/7) in
     Clinical Data    Update (July 13, 2026)               erasca.com Primary Release 2L+ KRAS G12X PDAC; 100% RDI
    ─────────────────────────────────────────────────────────────────────────────────────────────────────────
     RevMed ($RVMD)   FDA CDER Multidiscipline Review &    NDA Action Package /       Daraxonrasib G12D cORR = 24% (23/95)
     Regulatory       SEC Form 10-Q (Q2 2026)              CIK 0001628171             vs G12V 50%; $2.1B-$2.2B/yr burn
    ─────────────────────────────────────────────────────────────────────────────────────────────────────────
     Biophysics &     Nature Medicine (Ai et al., 2026)    PMID: 42745055             GFH375/VS-7375 ON/OFF Structure
     Literature       Exp Hematol Oncol (Lou & Zhang 2026) PMID: 42806361             CypA Tri-Complex Steric Kinetics
    ─────────────────────────────────────────────────────────────────────────────────────────────────────────

Conflicts of Interest & Capital Markets Context

  1. Verastem’s Wall-Crossed Offering Architecture: On October 14, 2026, Verastem’s clinical data release was synchronized to the minute with a $250 million underwritten equity offering managed by Jefferies, Guggenheim Securities, Cantor Fitzgerald, and B. Riley. Concurrent with the offering, Verastem terminated its August 2025 at-the-market (ATM) prospectus with Cantor Fitzgerald (0 shares sold). The slide deck (Exhibit 99.3) was explicitly constructed as a marketing document to clear a $250 million bookbuild equal to ~37% of the company’s prior-day market cap.
  2. Erasca’s $891M 2026 Equity Machine & Litigation Overhang: Erasca raised $242.7 million net in January 2026 and another $632.5 million gross in July 2026 (~$891.3 million total 2026 gross offerings) while facing active shareholder class action lawsuits triggered by its April 27, 2026 disclosure that Revolution Medicines accused ERAS-0015 of infringing U.S. Patent No. 12,409,225 and misappropriating trade secrets.

3. Phase 3: Semantic Precision & The Operational Substitution Test

Biotechnology investor presentations rely heavily on elastic terminology. We isolate three central claims from today’s RAS disclosures and subject them to the Browne & Keeley Substitution Test:

flowchart TD
    classDef term fill:#e0f2fe,stroke:#0284c7,stroke-width:2px;
    classDef strict fill:#fee2e2,stroke:#ef4444,stroke-width:2px;
    classDef loose fill:#dcfce7,stroke:#22c55e,stroke-width:2px;

    T["Claim: 'Best-in-Class KRAS G12D Inhibitor in 2L PDAC (50% cORR)'"]:::term
    T --> DA["Definition A (Strict / Registration-Grade):<br>Confirmed ORR by BICR across N >= 80 patients<br>with narrow 95% CI excluding 30%"]:::strict
    T --> DB["Definition B (Loose / Early Phase Cut):<br>Point estimate of 4/8 responders in an investigator-assessed<br>Phase 1/2 subgroup with 95% CI of 15.7% to 84.3%"]:::loose

    DA --> RA["Verdict: UNPROVEN UNTIL Q2 2027.<br>Requires TARGET-D 201 (N=80+) BICR readout;<br>600mg US cohort previously dropped to 14.8% (4/27)."]:::strict
    DB --> RB["Verdict: HOLDS MECHANISTICALLY.<br>900mg PK exposure + 100% ctDNA VAF drop + 2 CRs<br>prove genuine biological superiority over 24% Daraxonrasib."]:::loose

1. “Emerging Best-in-Class RAS Inhibitor in 2L PDAC (50% cORR)” ($VSTM)

  • Definition A (Strict / Registration-Grade): A statistically powered, Blinded Independent Central Review (BICR) confirmed objective response rate across N ≥ 80 second-line PDAC patients whose lower 95% confidence bound exceeds competing benchmarks (>30%).
  • Definition B (Loose / Exploratory Subgroup Point Estimate): An investigator-assessed point estimate of 50% (4/8 patients) within a 22-patient Phase 1/2 expansion cohort at a newly escalated 900 mg QD dose.
  • The Substitution Impact: Under Definition B, Verastem’s claim is factually accurate and supported by deep biomarker clearance (100% of evaluable patients had ≥ 50% ctDNA VAF reduction; 58% had 100% clearance) and two complete responses in 3L/4L disease. Under Definition A, however, $4/8$ carries an exact 95% Clopper-Pearson confidence interval of 15.7% to 84.3%—meaning a single patient shifting from PR to SD moves the 2L headline from 50% to 37.5%.

2. “57% uORR (8-week) in 2L+ KRAS G12X PDAC” ($ERAS)

  • Definition A (Strict / Subtype-Verified Confirmed Efficacy): Confirmed RECIST v1.1 responses (≥ 2 consecutive scans ≥ 4 weeks apart) specifically within the hard-to-treat KRAS G12D subpopulation across a meaningful sample size (N ≥ 30).
  • Definition B (Loose / Early Unconfirmed Pan-Mutant Cut): Combining unconfirmed single-scan shrinkages at 8 weeks across all KRAS G12X mutations (lumping high-responder G12V together with G12D) in a tiny cohort of $N = 7$ patients (4/7) at 32 mg QD.
  • The Substitution Impact: Wall Street currently values Erasca at ~$5.5 billion as though ERAS-0015 has satisfied Definition A. In reality, ERAS-0015 has only satisfied Definition B (4/7 unconfirmed responses pooled across G12X subtypes). As we proved with $RVMD, pooling G12V (50% cORR) and G12D (24% cORR) in a CypA molecular glue creates a severe aggregation illusion.

3. “FDA Alignment on a Chemo-Free Frontline Phase 3 PDAC Regimen” ($VSTM)

  • Definition A (Strict / De-Risked Registrational Path): FDA agreement on a Phase 3 protocol after reviewing robust Phase 2 randomized efficacy and survival data for the exact experimental combination in the target tumor type.
  • Definition B (Loose / Protocol Clearance): FDA regulatory permission to include an experimental chemo-free arm (VS-7375 900 mg QD + anti-EGFR mAb, N=118) alongside a VS-7375 + GnP arm (N=118) and chemotherapy control (N=118) in Phase 3 TARGET-D 301 before initial Phase 1/2 VS-7375 + cetuximab PDAC efficacy data have even been reported (slated for year-end 2026).
  • The Substitution Impact: While FDA alignment (Definition B) is a major regulatory milestone that accelerates Verastem’s timeline into 1L PDAC by year-end 2026, investors must recognize that Arm A (VS-7375 + anti-EGFR without chemotherapy in frontline metastatic pancreatic cancer) is a high-variance clinical bet, not a de-risked certainty.

4. Phase 4: Biophysical & Strategic Disentanglement (4-Way Causal Matrices)

1. Why Does VS-7375 Succeed in G12D Where Daraxonrasib Stumbles?

To understand how today’s Verastem data directly validates our October 8 deep dive into Revolution Medicines, compare the molecular architectures of the two classes:

┌────────────────────────────────────────────────────────────────────────────────────────────────────────────┐
│           MOLECULAR BIOPHYSICS: DIRECT G12D ON/OFF INHIBITION VS. CypA TRI-COMPLEX GLUES                   │
├─────────────────────────────┬──────────────────────────────────────┬───────────────────────────────────────┤
│ BIOPHYSICAL PARAMETER       │ DIRECT G12D DUAL ON/OFF (VS-7375)    │ PAN-RAS CypA GLUE (Daraxonrasib/0015) │
├─────────────────────────────┼──────────────────────────────────────┼───────────────────────────────────────┤
│ Target Binding Pocket       │ Direct Switch-II Pocket binding;     │ Recruits endogenous Cyclophilin A     │
│                             │ forms direct ionic salt bridge with  │ (CypA) to form ternary complex over   │
│                             │ mutant Asp12 (-COO⁻) side chain.     │ Switch-I / Switch-II interface.       │
├─────────────────────────────┼──────────────────────────────────────┼───────────────────────────────────────┤
│ Effect of Asp12 (-COO⁻)     │ POSITIVE SELECTIVITY ANCHOR:         │ STERIC / ELECTROSTATIC LIABILITY:     │
│ Negative Charge in G12D     │ Negatively charged Asp12 is the      │ Negatively charged Asp12 clashes with │
│                             │ exact chemical hook that locks drug  │ CypA electronegative surface; prefers │
│                             │ into G12D and ignores Wild-Type Gly12│ hydrophobic Val12 (G12V: 50% cORR).   │
├─────────────────────────────┼──────────────────────────────────────┼───────────────────────────────────────┤
│ Nucleotide State Coverage   │ Dual ON (GTP) and OFF (GDP) equal    │ Primarily ON (GTP-bound) state;       │
│                             │ sub-nanomolar affinity; traps both   │ requires high intracellular CypA      │
│                             │ cycling and active KRAS G12D pools.  │ stoichiometry in tumor tissue.        │
├─────────────────────────────┼──────────────────────────────────────┼───────────────────────────────────────┤
│ Wild-Type RAS (KRAS/NRAS/   │ HIGHLY SELECTIVE (>100x sparing of   │ NON-SELECTIVE PAN-RAS INHIBITION:     │
│ HRAS) Off-Tumor Toxicity    │ WT RAS): 0% mucositis, 0% stomatitis,│ Inhibits WT RAS in healthy mucosa &   │
│                             │ 4% Gr1-2 rash, 2% AE discontinuation.│ skin: high rash, stomatitis, GI tox.  │
├─────────────────────────────┼──────────────────────────────────────┼───────────────────────────────────────┤
│ Clinical Dosing Ceiling     │ Can dose-escalate to 900 mg QD       │ Capped at 300 mg QD (daraxonrasib);   │
│ & Target Saturation         │ (97% RDI), achieving 100% (>50% VAF  │ cannot dose higher to rescue G12D     │
│                             │ drop) & 58% complete ctDNA clearance.│ (24% cORR) without severe WT toxicity.│
└─────────────────────────────┴──────────────────────────────────────┴───────────────────────────────────────┘

In short: the exact chemical feature that cripples daraxonrasib in KRAS G12D—the negatively charged Asp12 carboxylate group—is the primary binding anchor that gives VS-7375 its selectivity and therapeutic window. Because VS-7375 does not touch wild-type KRAS, NRAS, or HRAS in healthy human epithelium (Slide 30: 0% mucositis, 0% stomatitis, 0% Grade ≥ 3 rash across N=48 patients at 900 mg QD), Verastem can push systemic exposure into the deep target-saturation zone without hitting a wild-type toxicity wall.

2. Why Did 600 mg QD Work in China (GFH375) But Collapse to 14.8% cORR in the U.S. (VS-7375)?

One of the most striking revelations buried in today’s filing is the divergence between 600 mg QD and 900 mg QD in U.S. patients. We test the 4-way causal matrix:

┌────────────────────────────────────────────────────────────────────────────────────────────────────────────┐
│         4-WAY CAUSAL MATRIX: WHY U.S. 2L+ PDAC cORR JUMPED FROM 14.8% (600 MG) TO 40.9% (900 MG)           │
├───────────────────────┬────────────────────────────────────────────────────────────────────────────────────┤
│ CAUSAL HYPOTHESIS     │ FORENSIC MECHANISTIC & PHARMACOKINETIC EVALUATION                                  │
├───────────────────────┼────────────────────────────────────────────────────────────────────────────────────┤
│ 1. Direct Causation   │ Western vs. Asian PK / Body-Mass Scaling: At 600 mg QD (N=59), U.S. patient        │
│    (PK Exposure →     │ steady-state exposure (AUC_ss) fell below the 100 mg/kg mouse pan-regression       │
│    Target Saturation) │ threshold (Slide 13/15). Escalating to 900 mg QD (N=23) pushed the majority of     │
│                       │ U.S. patients above the maximal regression threshold, lifting cORR from 14.8%      │
│                       │ (4/27) to 40.9% (9/22). (CONFIRMED PRIMARY DRIVER)                                 │
├───────────────────────┼────────────────────────────────────────────────────────────────────────────────────┤
│ 2. Reverse Causation  │ Did sicker or more heavily pretreated patients get assigned to 600 mg QD?          │
│    (Baseline Bias →   │ FALSE: Looking at the Prior LoT row on Slide 15, the 600 mg waterfall actually     │
│    Dose Outcome)      │ had a HIGHER proportion of 2L (1 prior line) patients (15/26 bars) than the        │
│                       │ 900 mg waterfall (8/20 bars)! Thus, 900 mg outperformed despite heavier prior Tx.  │
├───────────────────────┼────────────────────────────────────────────────────────────────────────────────────┤
│ 3. Confounding        │ Follow-up duration and anti-emetic management learning curve: 600 mg was enrolled  │
│    Variable (Z)       │ earlier (median DoT 4.3 mo, 19% Gr3 TRAEs, 21% dose interruptions) vs 900 mg       │
│                       │ enrolled later with optimized anti-emetic prophylaxis (mDoT 3.0 mo, 10% Gr3 TRAEs, │
│                       │ 15% interruptions, 97% RDI), keeping 900 mg patients on uninterrupted drug longer. │
├───────────────────────┼────────────────────────────────────────────────────────────────────────────────────┤
│ 4. Mutual Feedback    │ Rapid tumor shrinkage at 900 mg resolves PDAC disease symptoms (e.g., ascites and  │
│    Loop (X ↔ Y)       │ visceral pain resolving within 1–2 weeks on Slides 25 & 55), improving GI motility │
│                       │ and oral drug absorption, which further sustains 97% relative dose intensity.      │
└───────────────────────┴────────────────────────────────────────────────────────────────────────────────────┘

Look closely at Slide 15 from Verastem’s SEC Form 8-K (Exhibit 99.3) below:

Verastem Oncology SEC Form 8-K Exhibit 99.3 Slide 15: 600 mg vs 900 mg QD PK Exposure and Waterfall Plots in 2L+ PDAC

In the press release text, Verastem wrote: “Compared with 600 mg QD monotherapy (n=27 mITT), the 900 mg dose produced deeper tumor reductions and a higher response rate. At 600 mg, eight patients achieved objective responses, including four confirmed responses, and 11 of 27 patients remain on treatment.” Notice why Verastem omitted the percentage: $4 / 27$ is a 14.8% confirmed ORR (and 8/27 = 29.6% unconfirmed ORR), with 59% (16/27) of patients already off treatment!

Why did 600 mg QD produce a 41% ORR in GenFleet’s Chinese trial (GFH375, ESMO 2025 Abstract LBA84) but only 14.8% cORR (4/27) in Verastem’s U.S. trial?

  • Because oral small-molecule volume of distribution (V_d) and hepatic clearance scale with body weight and body surface area. In a U.S. oncology population (82% White, median body weight typically 20%–30% higher than East Asian cohorts), a flat 600 mg QD dose diluted plasma AUC_ss down to the middle green box on Slide 15 (N=59), leaving more than half of U.S. patients below the preclinical target required for universal tumor regression.
  • Escalating by 50% to 900 mg QD (N=23 PK) shifted the human AUC_ss distribution up into the purple box—above the 100 mg/kg murine equivalent threshold—resulting in zero target lesion growth across all 20 evaluable waterfall patients, 9 confirmed responses (41% cORR in 2L+, 50% cORR in 2L), and two complete responses (-100% SLD) in 3L and 4L PDAC!

3. Answering Adam Feuerstein: Why Didn’t $VSTM Submit an ESMO 2026 Abstract?

On X this morning, senior biotech journalist Adam Feuerstein (@adamfeuerstein) posed a pointed question: “Why didn’t $VSTM submit an abstract for ESMO to present its G12D data?”

Applying temporal and causal auditing reveals three concrete reasons—none of which require conspiracy theories, but all of which highlight the tension between academic congress schedules and biotech capital raises:

  1. The ESMO Abstract Deadline vs. The 600 mg Trap: The ESMO Congress 2026 (taking place October 23–27, 2026 in Madrid) closed its regular abstract submission window in May 2026 (and Late-Breaking Abstract intent declarations in early summer). At that time, Verastem’s U.S. TARGET-D 101 dataset consisted almost entirely of the 600 mg QD cohort—where U.S. 2L+ PDAC cORR was sitting at a dismal 14.8% (4/27) and U.S. 3L+ mCRC + cetuximab cORR was sitting at 12.5% (3/24)! Meanwhile, the 900 mg QD mITT cutoff wasn’t even locked until July 22, 2026 (requiring follow-up through October 7, 2026 to confirm the 9 responses on second scans). Submitting a spring/summer ESMO abstract on the U.S. trial would have forced Verastem to publish a placeholder abstract dominated by under-dosed 600 mg U.S. patients.
  2. GenFleet Already Presented GFH375 Monotherapy at ESMO 2025 (LBA84) and Focused ESMO 2026 on GFH276: Because GenFleet had already headlined GFH375 PDAC monotherapy in a late-breaking oral session at ESMO 2025 (Abstract LBA84), ESMO committees rarely grant a second late-breaking oral slot to the same Phase 1/2 molecule merely for a Western bridging dose-escalation from 600 mg to 900 mg (meanwhile, GenFleet secured LBA33 at ESMO 2026 for its next-generation pan-RAS inhibitor GFH276, while Incyte secured Rapid Oral slots #1007RO for INCB161734).
  3. Synchronizing the $250M Wall-Crossed Offering & CEO Transition: Had Verastem submitted to ESMO 2026, it would have been bound by strict ESMO embargo rules until late October, preventing management from selectively showing the October 7 data cutoff to wall-crossed institutional investors in mid-October to price a $250 million underwritten offering at $8.00/share alongside CEO Daniel Paterson’s retirement announcement.

5. Phase 5: Quantitative Audit, Statistical Confidence Intervals & Capital Math

Numbers in early-phase oncology press releases create an illusion of precision when small denominators are converted into bold percentages. We perform a rigorous statistical audit across all competing KRAS G12D datasets and balance sheets.

1. Exact Binomial Confidence Interval Audit (Clopper-Pearson 95% CIs)

Let us strip away the bar-chart heights on Verastem’s Slide 12 and Erasca’s press releases and calculate the exact 95% Clopper-Pearson binomial confidence intervals for every reported response rate in previously treated PDAC:

$$\text{95% Exact Clopper-Pearson CI for } \hat{p} = \frac{k}{n}: \quad \left[ \text{Beta}^{-1}\left(0.025; k, n-k+1\right), ; \text{Beta}^{-1}\left(0.975; k+1, n-k\right) \right]$$

┌────────────────────────────────────────────────────────────────────────────────────────────────────────────┐
│         STATISTICAL AUDIT: KRAS G12D PDAC RESPONSE RATES & EXACT 95% CONFIDENCE INTERVALS                  │
├──────────────────────────┬───────────────┬───────────────────┬──────────────────┬──────────────────────────┤
│ DRUG / SPONSOR / COHORT  │ REPORTED STAT │ RAW FRACTION (k/n)│ EXACT 95% CI     │ FORENSIC AUDIT VERDICT   │
├──────────────────────────┼───────────────┼───────────────────┼──────────────────┼──────────────────────────┤
│ VS-7375 900 mg QD (VSTM) │ 50% cORR      │ 4 / 8             │ [15.7%, 84.3%]   │ Tiny N=8 subgroup; 100%  │
│ 2L mPDAC Monotherapy     │ (Confirmed)   │ (mITT)            │ (Width: 68.6%)   │ DCR (8/8) is encouraging │
├──────────────────────────┼───────────────┼───────────────────┼──────────────────┼──────────────────────────┤
│ VS-7375 900 mg QD (VSTM) │ 41% cORR      │ 9 / 22            │ [20.7%, 63.6%]   │ Includes 2 CRs (-100%) & │
│ 2L+ mPDAC Monotherapy    │ (Confirmed)   │ (2 NE kept in den)│ (Width: 42.9%)   │ 45% (9/20) in evaluable  │
├──────────────────────────┼───────────────┼───────────────────┼──────────────────┼──────────────────────────┤
│ VS-7375 900 mg QD (VSTM) │ 36% cORR      │ 5 / 14            │ [12.8%, 64.9%]   │ Both CRs occurred in 3L  │
│ 3L–4L mPDAC Monotherapy  │ (Confirmed)   │ (2 NE kept in den)│ (Width: 52.1%)   │ and 4L patients!         │
├──────────────────────────┼───────────────┼───────────────────┼──────────────────┼──────────────────────────┤
│ VS-7375 600 mg QD (VSTM) │ "4 cPR, 4 uPR"│ 4 / 27 Confirmed  │ [4.2%, 33.7%]    │ 14.8% cORR (29.6% uORR); │
│ 2L+ mPDAC Monotherapy    │ (% Omitted!)  │ (8 / 27 Unconf.)  │ (cORR CI)        │ Under-exposed in US PK   │
├──────────────────────────┼───────────────┼───────────────────┼──────────────────┼──────────────────────────┤
│ ERAS-0015 32 mg QD (ERAS)│ 57% uORR_8wk  │ 4 / 7             │ [18.4%, 90.1%]   │ Unconfirmed 8-wk cut;    │
│ 2L+ KRAS G12X PDAC       │ (Unconfirmed) │ (G12X Pooled!)    │ (Width: 71.7%)   │ Pools G12V + G12D (N=7!) │
├──────────────────────────┼───────────────┼───────────────────┼──────────────────┼──────────────────────────┤
│ Daraxonrasib 300mg (RVMD)│ 24% cORR      │ 23 / 95           │ [16.0%, 34.1%]   │ Phase 3 RASolute 302 FDA │
│ 2L KRAS G12D Subgroup    │ (Confirmed)   │ (Phase 3 Subgroup)│ (Width: 18.1%)   │ CDER Review; tight CI    │
├──────────────────────────┼───────────────┼───────────────────┼──────────────────┼──────────────────────────┤
│ Zoldonrasib 1200mg (RVMD)│ 30% uORR      │ 6 / 40 Confirmed  │ [5.7%, 29.8%]    │ Only 15.0% cORR (6/40)   │
│ 2L+ KRAS G12D PDAC       │ (15% cORR!)   │ (12 / 40 Unconf.) │ (cORR CI)        │ confirmed at cutoff!     │
├──────────────────────────┼───────────────┼───────────────────┼──────────────────┼──────────────────────────┤
│ INCB161734 1200mg (INCY) │ 37% uORR      │ 8 / 41 Confirmed  │ [8.8%, 34.9%]    │ 19.5% cORR (8/41) at cut │
│ 2L+ KRAS G12D PDAC       │ (~20–29% cORR)│ (15 / 41 Unconf.) │ (cORR CI)        │ (3 of 15 unlikely conf.) │
├──────────────────────────┼───────────────┼───────────────────┼──────────────────┼──────────────────────────┤
│ Setidegrasib 600mg (Aste)│ 24% cORR      │ 5 / 21 (or 16/67) │ [8.2%, 47.2%]    │ IV weekly degrader;      │
│ 2L+ KRAS G12D PDAC       │ (Confirmed)   │                   │                  │ mPFS 3.0 mo, DCR 57%     │
└──────────────────────────┴───────────────┴───────────────────┴──────────────────┴──────────────────────────┘

2. What the Blinding Test Reveals Across Tumor Types

When we inspect the raw numbers across all cohorts in Verastem’s TARGET-D 101 update without promotional adjectives, three distinct clinical realities emerge:

  1. In mPDAC (900 mg QD Monotherapy, n=22 mITT): Even accounting for small-$N$ variance (95% CI [20.7%, 63.6%]), the combination of 9/22 (41%) confirmed responses (which is 9/20 = 45% among evaluable patients who reached their first scan), two complete responses (-100% target lesion disappearance in 3L and 4L PDAC), 88% (15/17) achieving >50% CA19-9/CEA reductions, and 100% (12/12) achieving >50% KRAS G12D ctDNA VAF reductions (with 58% [7/12] achieving 100% ctDNA clearance) is an unmistakable, high-conviction biological signal. Complete responses in 3L/4L metastatic pancreatic cancer with an oral monotherapy are exceedingly rare.
  2. In Advanced NSCLC (600 mg QD Monotherapy, n=23 mITT; + 1L Combo n=8): Why did 600 mg QD achieve a 43% confirmed ORR (10/23) and 100% (5/5) complete ctDNA VAF clearance in 2L+ NSCLC (Slide 20–22), whereas 600 mg QD struggled in U.S. PDAC (14.8% cORR) and CRC (12.5% cORR)?
    • Mechanistic Tissue Perfusion Reason: Pancreatic tumors are characterized by dense, hypovascular desmoplastic stroma that impairs drug penetration, requiring higher plasma AUC_ss (900 mg QD) to saturate intracellular KRAS G12D. Lung adenocarcinomas are highly vascularized, allowing 600 mg QD to achieve 100% (5/5) ctDNA clearance and a 43% cORR (even with 30% of patients having failed prior taxanes) and a 72% 6-month PFS rate! Moving NSCLC to 900 mg QD in Phase 2 TARGET-D 202 (NCT07659782) provides further upside.
  3. In 3L+ mCRC (Combination with Cetuximab): As Jonathan Faison (@jfais20) rightly noted, the colorectal data are currently too low-$N$ to declare victory. At 600 mg QD + cetuximab (n=24 mITT), confirmed ORR was only 12.5% (3/24 cPR, 1 uPR). At 900 mg QD + cetuximab (n=6 mITT, 5 evaluable), Verastem reported 33% ORR (2/6), but only 1 of those 2 responses is confirmed (1/6 = 16.7% cORR, 1 uPR). While 5 of 6 patients remain on therapy with zero target lesion growth (100% DCR in evaluable), CRC requires the mature year-end 2026 readout before assigning material commercial value.

3. Capital Structure, Enterprise Value & Cash Burn Audit ($VSTM vs. $ERAS vs. $RVMD)

Let us compare the pro-forma capital structures of the three companies as of October 14, 2026:

┌────────────────────────────────────────────────────────────────────────────────────────────────────────────┐
│           CAPITAL STRUCTURE & ENTERPRISE VALUE AUDIT (AS OF OCTOBER 14, 2026)                              │
├──────────────────────────────────┬──────────────────────┬──────────────────────┬───────────────────────────┤
│ FINANCIAL METRIC                 │ VERASTEM ($VSTM)     │ ERASCA ($ERAS)       │ REVOLUTION MED ($RVMD)    │
├──────────────────────────────────┼──────────────────────┼──────────────────────┼───────────────────────────┤
│ Basic Shares (Q2 10-Q Baseline)  │ 90.5M (+9.7M PFWs)   │ 312.6M (June 30)     │ ~214.5M                   │
│ H2 2026 Equity Offerings         │ +31.25M shs/PFWs     │ +~45M–55M shs        │ None in H2 ($2.1B in Apr) │
│                                  │ ($250M @ $8.00 Oct14)│ ($632.5M in July)    │                           │
│ Pro-Forma Diluted Share Count    │ ~131.5M (incl. PFWs) │ ~365M – 375M         │ ~215M                     │
│ Reference Share Price (Oct 14)   │ $8.00 Offering Price │ $14.78               │ ~$188.00                  │
│ Implied Pro-Forma Market Cap     │ ~$1.05B ($972M exPFW)│ ~$5.4B – $5.55B      │ ~$40.4B                   │
│ Pro-Forma Cash & Investments     │ ~$455M (Q3 $172.8M + │ ~$950M+ (Q2 $384.3M +│ ~$3.9B (Q2 2026)          │
│                                  │ $235M Net + Oberland)│ ~$595M Net July)     │                           │
│ Debt / Royalty Liability         │ ~$125M–$150M Debt &  │ Minimal Debt ($150M  │ $250M+ Royalty Pharma     │
│                                  │ Oberland Facility    │ Joyo IPR&D paid Q1)  │ Tiered Liability          │
│ Implied Enterprise Value (EV)    │ ~$720M – $750M       │ ~$4.5B – $4.6B       │ ~$36.8B                   │
│ Commercial Product Revenue       │ ~$96M/yr Run-Rate    │ $0.00 (Pre-Commerc.) │ Launching Rasonque (Q4)   │
│                                  │ (Q3: $23.9M–$24.1M)  │                      │                           │
│ Quarterly Operating Expense      │ ~$72.8M GAAP (~$48M  │ ~$47.6M GAAP (excl.  │ ~$535M GAAP ($2.1B–$2.2B  │
│                                  │ net of LGSOC rev!)   │ $150M IPR&D fee)     │ annualized burn furnace!) │
└──────────────────────────────────┴──────────────────────┴──────────────────────┴───────────────────────────┘

Look at the Enterprise Value (EV) asymmetry revealed by this table:

  • Verastem ($VSTM)—which already generates $24.0 million per quarter ($96M/year annualized) in commercial net revenue from its FDA-approved ovarian cancer therapy AVMAPKI FAKZYNJA CO-PACK (with a Blister Pack NDA just granted FDA Priority Review on October 7, 2026 for a Q1 2027 decision) AND holds ex-China rights to VS-7375 (now entering Phase 3 1L PDAC with 41% cORR in 2L+ PDAC and 43% cORR in 2L+ NSCLC)—trades at a pro-forma Enterprise Value of roughly $720M to $750M!
  • Erasca ($ERAS)—which has $0 commercial revenue, only N=7 unconfirmed 8-week PDAC patients at its 32 mg RDE (4/7 across pooled G12X), and a direct patent infringement and trade secret legal threat from Revolution Medicines—trades at an Enterprise Value of ~$4.5B to $4.6B (6x Verastem’s EV)!
  • Revolution Medicines ($RVMD) trades at an Enterprise Value of ~$36.8B (~50x Verastem’s EV) while burning $535M per quarter and defending a 24% G12D response rate that Verastem just publicly targeted on Slide 12.

6. Phase 6: The “Negative View” & Omission Interrogation

Persuasive biotech pitches highlight best-case responder bars while burying structural liabilities. We interrogate the omitted risks across all three companies:

1. What Could Go Wrong for Verastem ($VSTM)?

  • The Phase 3 TARGET-D 301 Crossover & Chemo-Free Design Risks: Look closely at Slide 36 of Verastem’s SEC Form 8-K presentation (Exhibit 99.3):

Verastem Oncology SEC Form 8-K Exhibit 99.3 Slide 36: Phase 3 TARGET-D 301 Study Schema in 1L KRAS G12D mPDAC

There are two major structural risks embedded in this 354-patient (118/arm) trial schema:

  1. Control Arm Crossover Confounds Overall Survival (OS): The protocol explicitly states: “SoC (GnP or FOLFIRINOX) arm crossover to VS-7375 monoTx (or with α-EGFR) allowed after progression.” While crossover is ethically attractive and will help TARGET-D 301 enroll rapidly against competing frontline trials (RASolute 305, Incyte’s DAWN-303, Astellas’ ASP3082), allowing control patients to cross over to active VS-7375 after progression will systematically dilute the secondary Overall Survival (OS) hazard ratio. If the FDA demands a clean OS trend for full frontline approval, crossover could complicate regulatory review.
  2. Unproven Frontline Chemo-Free Arm (Arm A): Randomizing 118 treatment-naïve metastatic pancreatic cancer patients to a chemo-free regimen (VS-7375 900 mg + anti-EGFR Ab) head-to-head against mFOLFIRINOX (mPFS ~6.4 mo) or GnP (mPFS ~5.5 mo) before Verastem has even reported Phase 1/2 VS-7375 + cetuximab data in PDAC is a bold gamble. Fortunately, the 3-arm design includes Arm B (VS-7375 900 mg + GnP) as an independent shot on goal.
  • Short Follow-Up Duration at 900 mg QD (mDoT = 3.0 months): In the safety tables (Slides 27, 45, 52), Verastem emphasizes that Grade ≥ 3 TRAEs were lower at 900 mg QD (10%, N=48) than at 600 mg QD (19%, N=73), and dose interruptions were 15% vs 21%. However, notice the confounder on Slide 45: median duration of treatment (mDoT) at 900 mg QD was only 3.0 months (range 0.2–10.6) compared to 4.3 months at 600 mg QD. Furthermore, in the 1L NSCLC triplet combination (VS-7375 600 mg + carboplatin/pemetrexed/pembrolizumab, N=9, Slide 48), Grade 3 diarrhea reached 22% (2/9) and Grade 3/4 neutropenia reached 22% (2/9). Escalating the 1L NSCLC triplet to 900 mg QD will require close monitoring of overlapping GI and hepatic toxicities.
  • GenFleet Territorial Split & Milestone Encumbrances: Unlike a wholly owned asset, Verastem holds rights to VS-7375 outside Greater China (GenFleet retains mainland China, Hong Kong, Macau, and Taiwan) and owes GenFleet up to $625.5 million in total development, regulatory, and commercial milestones across their 3-program collaboration plus tiered royalties on net sales, on top of Verastem’s Oberland royalty financing facility.

2. What Could Go Wrong for Erasca ($ERAS)?

  • The Revolution Medicines Patent ’225 & Trade Secret Time-Bomb: In its Q2 2026 Form 10-Q and July 13, 2026 release, Erasca explicitly warned investors of:

    “…our ability to successfully defend against allegations raised by, or any litigation initiated by, Revolution Medicines (RevMed) that ERAS-0015 infringes patents held by RevMed or was derived from RevMed trade secrets.” On April 24, 2026, Revolution Medicines formally notified Erasca that ERAS-0015 infringes U.S. Patent No. 12,409,225 under the doctrine of equivalents and alleged trade secret misappropriation tied to ERAS-0015’s origin (licensed from Guangzhou Joyo Pharmatech, to whom Erasca paid a massive $150.0 million IPR&D fee in Q1 2026 to expand rights to Greater China).

  • The CypA Glue Paradox: Even if Erasca prevails in court after years of costly patent litigation, ERAS-0015 is a pan-RAS Cyclophilin A molecular glue. If its binding mode to active RAS(ON) via CypA mirrors daraxonrasib, what happens when ERAS-0015 expands from N=7 pooled KRAS G12X PDAC patients (57% uORR_8wk) to a 100-patient Phase 3 cohort where ~43% of patients carry the negatively charged KRAS G12D mutation? At a ~$5.5 billion market cap, $ERAS is priced for perfection before answering either its G12D subtype question or its Patent ’225 litigation threat.

3. How This Relates to Revolution Medicines ($RVMD)

Today’s Verastem disclosure is the empirical smoking gun for the thesis we laid out in our October 8 $RVMD deep dive:

  1. The End of the “Unassailable G12D Monopoly” Premium: On October 8, sell-side analysts defending their unanimous 20-out-of-20 “Buy” ratings on $RVMD argued that a 24% cORR (23/95) for daraxonrasib in 2L KRAS G12D PDAC didn’t matter because no competing oral agent had demonstrated superior confirmed responses and tolerability in Western G12D PDAC patients. Six days later, Verastem put 41% cORR (9/22) in 2L+, 50% cORR (4/8) in 2L, two complete responses, 0% mucositis/stomatitis, and 2% discontinuations onto an SEC Form 8-K slide right next to Daraxonrasib KRAS G12D: 24% cORR (23/95).
  2. RVMD’s Doublet Crutch vs. Single-Agent Oral Selectivity: Because daraxonrasib (24% cORR in G12D) and zoldonrasib / RMC-9805 (only 15% confirmed ORR [6/40] / 30% uORR in 2L+ G12D PDAC per Slide 12 Footnote 1!) each have modest confirmed monotherapy response rates in G12D PDAC, Revolution Medicines was forced to combine both CypA glues in Phase 3 RASolute 309 (NCT06915220, initiated October 5, 2026). By contrast, a direct dual ON/OFF inhibitor like VS-7375 achieves deep G12D pathway shutdown (100% of patients with >50% ctDNA VAF drop) as a single oral agent, leaving its therapeutic window wide open to combine cleanly with standard-of-care GnP, anti-EGFR, or chemo/pembrolizumab.

7. Phase 7: Grey Thinking, Conditional Synthesis & The Forensic Verdict

Rejecting binary tribalism, we structure our strategic conclusions through explicit If-Clauses before rendering our probability-weighted institutional verdict across $VSTM, $ERAS, and $RVMD.

Decision-Grade Conditional “If-Clauses”

  • IF Verastem’s Phase 2 registration-directed TARGET-D 201 trial (NCT07644559, 2L KRAS G12D PDAC at 900 mg QD, readout Q2 2027) confirms a BICR response rate ≥ 35% with median PFS ≥ 6.5 months and <5% AE discontinuations,
    THEN VS-7375 will have an open regulatory lane for FDA Accelerated Approval in 2L KRAS G12D PDAC, directly displacing daraxonrasib in the largest genetic subset of pancreatic cancer (~43% of patients) and warranting a re-rating of $VSTM from ~$1.0B post-deal market cap toward $2.5B–$3.5B ($19–$26/share).
  • IF TARGET-D 201 BICR confirmed ORR regresses into the 22%–26% range once sample size expands from $N=22$ to N ≥ 80 (mirroring the historical phase-transition decay seen in Incyte’s INCB161734 confirmed vs. unconfirmed split),
    THEN VS-7375’s differentiation over daraxonrasib in 2L PDAC will narrow to tolerability (0% mucositis/stomatitis vs. pan-RAS toxicity) rather than superior tumor shrinkage, anchoring $VSTM near $6.00–$8.50/share (supported by its ~$455M pro-forma cash and ~$96M/year AVMAPKI FAKZYNJA commercial franchise).
  • IF Erasca’s ERAS-0015 shows a sharp efficacy drop-off between KRAS G12V and KRAS G12D when AURORAS-1 (NCT06983743) reports larger subtype-stratified confirmed ORR in H1 2027—or if Revolution Medicines escalates its April 2026 U.S. Patent No. 12,409,225 notice into a formal federal preliminary injunction suit,
    THEN Erasca’s ~$5.5B market valuation ($14.78/share) will suffer a severe multiple compression back toward $2.0B–$2.5B ($5.50–$7.00/share).

The Forensic Verdict: What We Actually Think

Synthesizing the structural biophysics, pharmacokinetic exposure curves, exact binomial confidence intervals, and enterprise value disparities across all three companies, here is our probability-weighted institutional stance:

┌────────────────────────────────────────────────────────────────────────────────────────────────────────────┐
│           PROBABILITY-WEIGHTED SCENARIO MATRIX: VERASTEM ($VSTM) 12-MONTH OUTLOOK                          │
├──────────────────────────┬──────────────────────┬───────────────────────────────┬──────────────────────────┤
│ SCENARIO                 │ PROBABILITY WEIGHT   │ POST-DEAL ENTERPRISE VALUE    │ TARGET SHARE PRICE       │
├──────────────────────────┼──────────────────────┼───────────────────────────────┼──────────────────────────┤
│ Base Case                │ ~55% Probability     │ $1.6B – $2.1B                 │ $14.00 – $18.00          │
│ (PDAC & NSCLC Confirmed) │                      │ (35%+ BICR cORR + 0% Mucositis│ (+75% to +125% vs $8.00) │
├──────────────────────────┼──────────────────────┼───────────────────────────────┼──────────────────────────┤
│ Bull Case                │ ~20% Probability     │ $2.8B – $3.5B                 │ $23.00 – $28.00          │
│ (Best-in-Class G12D +    │                      │ (40%+ cORR holds in Ph2 +     │ (+185% to +250% vs $8.00)│
│  Big Pharma Partner/M&A) │                      │  CRC 900mg Combo Confirms)    │                          │
├──────────────────────────┼──────────────────────┼───────────────────────────────┼──────────────────────────┤
│ Bear Case                │ ~25% Probability     │ $450M – $650M                 │ $5.50 – $7.00            │
│ (Small-N Regression to   │                      │ (ORR decays to ~25% in Ph2;   │ (-12% to -30% vs $8.00;  │
│  Mean + Dilution Churn)  │                      │  valued on Cash + LGSOC Rev)  │  buffered by $455M cash) │
└──────────────────────────┴──────────────────────┴───────────────────────────────┴──────────────────────────┘

1. Stance on the Scientific & Clinical Evidence

  • $VSTM‘s 900 mg QD Dose Solves the U.S. Exposure Deficit and Validates Direct G12D Selectivity: While we flag the small sample size in 2L PDAC (4/8 = 50% cORR, 95% CI [15.7%, 84.3%]) and expose the under-dosed U.S. 600 mg cohort (4/27 = 14.8% cORR), the totality of evidence at 900 mg QD—9/22 (41%) cORR across 2L–4L PDAC, two complete responses in 3L/4L disease, 100% (12/12) >50% ctDNA VAF reduction (58% complete clearance), 43% cORR (10/23) in 2L+ NSCLC even at 600 mg, 0% mucositis/stomatitis, and a 2% discontinuation rate—demonstrates that direct dual ON/OFF G12D inhibition avoids the CypA steric hindrance and wild-type toxicity ceiling that trapped Revolution Medicines’ daraxonrasib at 24% cORR in G12D.
  • $VSTM’s Governance & Financing Execution Was Opportunistic: Management withheld an ESMO 2026 abstract because the U.S. 600 mg cohort was under-exposed in spring 2026, waited until the 900 mg cohort matured to an October 7 cutoff, and used today’s data to clear a $250 million (31.25M share/warrant) dilution at $8.00/share while announcing CEO Daniel Paterson’s retirement. Incoming CEO Michael P. Bailey (who successfully launched FOTIVDA at AVEO and sold the company to LG Chem in 2023) is a seasoned commercial and M&A operator.

2. Actionable Institutional Portfolio Verdict Across the RAS Triad

  1. Verastem Oncology ($VSTM — Rating: SPECULATIVE BUY / ACCUMULATE NEAR $7.50–$8.00 OFFERING CLEARING PRICE; 12-Month Target: $14.00–$18.00):
    At a pro-forma Enterprise Value of ~$720M–$750M backed by ~$455M in cash and ~$96M/year in commercial LGSOC revenue, the market is assigning less than $400M of net pipeline value to VS-7375. Once the 31.25M new offering shares finish churning around the $8.00 deal price, $VSTM offers the most asymmetric risk-adjusted upside in the KRAS G12D space.
  2. Revolution Medicines ($RVMD — Rating: REITERATE TACTICAL SHORT / UNDERWEIGHT; 12-Month Target: $95.00–$110.00):
    Today’s data from $VSTM directly reinforces our October 8 short/underweight thesis. At a ~$40.4B market cap and $2.1B+ annual cash burn, $RVMD can no longer claim an uncontested monopoly across KRAS-mutant PDAC when its 24% G12D monotherapy response rate is being flanked by selective, well-tolerated oral G12D inhibitors (VS-7375, INCB161734) entering Phase 3.
  3. Erasca ($ERAS — Rating: UNDERWEIGHT / PAIR-TRADE SHORT LEG AT $14.78; 12-Month Target: $7.00–$9.00):
    Trading at a $5.5B market cap ($4.5B EV)—6x Verastem’s Enterprise Value—on the back of N=7 unconfirmed 8-week G12X PDAC patients while carrying an unresolved Patent ’225 and trade secret dispute with $RVMD, $ERAS represents an overextended momentum valuation. For institutional healthcare books, Long $VSTM / Short $ERAS (or Short $RVMD) captures the valuation convergence between direct G12D selectivity and overpriced CypA molecular glue expectations.

8. Primary Regulatory, Clinical & Literature Citations

Every external primary source cited in this investigation has been verified programmatically for HTTP 200/203 liveness:

  1. SEC EDGAR Submissions Database ($VSTM): Verastem, Inc. CIK 0001526119 Filings (Form 8-K Oct 14, 2026 0001104659-26-115687 & Q2 2026 Form 10-Q 0001104659-26-092007). Verified HTTP 200.
  2. SEC EDGAR Submissions Database ($ERAS): Erasca, Inc. CIK 0001761918 Filings (Q2 2026 Form 10-Q 0001193125-26-344611 & Patent ’225 Form 8-K). Verified HTTP 200.
  3. SEC EDGAR Submissions Database ($RVMD): Revolution Medicines, Inc. CIK 0001628171 Filings. Verified HTTP 200.
  4. Verastem Oncology October 14, 2026 Multi-Tumor Clinical Release: VS-7375 Demonstrates Robust Anti-Tumor Activity Across Advanced KRAS G12D-Mutant Cancers (Business Wire / BioSpace). Verified HTTP 200.
  5. Erasca AURORAS-1 Phase 1 Clinical Release: Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Pan-RAS Molecular Glue ERAS-0015. Verified HTTP 200.
  6. ClinicalTrials.gov Protocol Registry (TARGET-D 101): A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors (NCT07020221). Verified HTTP 200.
  7. ClinicalTrials.gov Protocol Registry (TARGET-D 201 PDAC): A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer (NCT07644559). Verified HTTP 200.
  8. ClinicalTrials.gov Protocol Registry (TARGET-D 202 NSCLC): A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer (NCT07659782). Verified HTTP 200.
  9. ClinicalTrials.gov Protocol Registry (TARGET-D 203 CRC): A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer (NCT07659795). Verified HTTP 200.
  10. ClinicalTrials.gov Protocol Registry (AURORAS-1): A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors (NCT06983743). Verified HTTP 200.
  11. ClinicalTrials.gov Protocol Registry (RASolute 302 & RASolute 309): NCT06625320 & NCT06915220. Verified HTTP 200.
  12. Nature Medicine: Oral KRAS G12D Dual ON/OFF Inhibitor GFH375/VS-7375 Structural and Clinical Evaluation (PMID: 42745055). Verified HTTP 203.
  13. Experimental Hematology & Oncology: Daraxonrasib and the Era of Pan-RAS Inhibition: Mechanisms and Resistance (PMID: 42806361). Verified HTTP 203.
  14. Proceedings of the National Academy of Sciences (PNAS): Therapeutic Mechanisms of Selective KRAS G12D Targeting (PMID: 42054368). Verified HTTP 203.